In the product segment of the urethral stricture treatment devices market, the urethral balloon dilation catheters category is expected to register a healthy CAGR in the urethral stricture treatment devices market during the forecast period.
This can be attributed to the advantages offered by these devices over their counterparts. Balloon dilation is a well-tolerated, safe, office-based procedure that offers multiple advantages over sequential rigid dilation and internal urethrotomy. It is associated with minimal complications.
Furthermore, urethral balloon dilation is considered as a minimally invasive technique that has the potential advantage of being less morbid and is technically less challenging to perform. It is also considered to be less traumatic than sequential rigid dilatation.
Owing to the advantages associated with the urethral balloon dilation catheters, there have been an increase in the development of newer products aimed at treating urethral strictures.
For instance, in December 2021, Urotronic received the regulatory approval from the US Food and Drug Administration for their product- Optilume, durg-coated urology balloon, which elutes a highly lipophilic drug, paclitaxel that limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.
Therefore, the advantages associated with urethral balloon dilation and the innovation in product development are expected to boost the demand for this product category thereby ultimately propelling the market for urethral balloon dilation catheters during the forecast period.
Learn more of Urethral Stricture Treatment Devices Companies
Also read-
Comments